Compare RLX Technology Inc (RLX) vs Revvity Inc (RVTY) Price & Performance

RLX trades at $1.73, unchanged on the day, and has recently set new 52-week lows. The technical outlook is bearish, with moving averages signaling selling pressure. Fundamentally, the company reported $3.62B in 2025 revenue and $921.87M net income, though recent quarters show earnings misses against expectations. International expansion, now 70% of revenue, drives growth, but margin compression is a concern. Analyst coverage is limited, with a single hold rating indicating caution.

The outlook is mixed; strong international growth and a discounted valuation (P/E 15.46, P/B 0.91) offer potential upside, but persistent earnings misses, bearish technicals, and regulatory risks in the e-vapor industry pose significant headwinds. Investor sentiment remains neutral to cautious amid recent price weakness.

Revvity (RVTY) trades at $154.18, up 0.38% today and near its 52-week high of $158.28. The stock shows a bullish technical trend with strong moving averages and has beaten earnings estimates for the last three quarters. Recent developments include the launch of a new diabetes screening kit in Europe and the acquisition of Human Cell Design to expand its metabolic disease research tools. Revenue remains stable around $2.9 billion, though net income margin is modest at 8.16%.

The outlook is positive with analyst consensus leaning buy (51.72%) and a price target of $132.13, though the current price exceeds it. Key opportunities include diagnostic growth and AI-driven demand, while risks involve premium valuation (P/E 73.15), margin pressures, and exposure to China market volatility. Earnings on November 3, 2026, will be critical for near-term direction.